ULyrica (pregabalin) isilwanyana esisetyenziselwa ukuphatha intlungu ye- fibromyalgia . Ukongezelela, i-FDA ivunyelwe ukuba isetyenziswe kwi- neuropathy yesifo sikashukela kunye ne-neuralgia ye-posterpetic (shingles). Kwakhona imishanguzo yokuchaphazela.
I-FDA ivume iLyrica kwi-fibromyalgia ngoJuni 2007, eyenza ibe yiyobisi lokuqala eliye lavunyelwa le meko. Kuze kube ngoku, akukho nhlobo ye-Lyrica.
Ilingana elisondeleyo yi-gabapentin, eyona hlobo lwe-generic ye-Neurontin yeziyobisi, efana ne-Lyrica. (Enyanisweni, iLyrica idla ngokuba yi "son of Neurontin.") Nangona kunjalo, iziyobisi azifani, ngoko umzimba wakho ungasabela ngokwahlukileyo kubo.
ULyrica ungomnye wezidakamizwa ezintathu ze-FDA ezivunyiweyo ze-fibromyalgia kwaye nguyena kuphela ongenakuhlulwa njenge-anti-depressant. Olunye unyango luyiCymbalta (duloxetine) kunye no- Savella (milnacipran) .
Indlela eLyrica isebenza ngayo
I-Fibromyalgia ikholelwa ukuba iquka iimbilini kunye ne-dysregulation ye- neurotransmitters (izithunywa zamakhemikhali) ezithumela imiyalezo, kubandakanywa izibonakaliso zentlungu, phakathi kweeseli zengqondo.
Izazinzulu aziqondi kakuhle ukuba uLyrica uphucula njani iimpawu ze-fibromyalgia. Nangona kunjalo, isicatshulwa sikholwa ukuba sinciphise iimpembelelo ezithile kwiingqondo kwaye ziyeke iimbilini ezisebenzayo. Kwakhona kunokuchaphazela indlela ezithile ze-neurotransmitters ezisebenzayo.
ELyrica kwiFibromyalgia
Nangona ivunyiwe iminyaka emininzi, uphando luye lwaqhubeka eLyrica njengonyango lwe-fibromyalgia.
Enyanisweni, ukuba i-FDA ivunywe, iimvavanyo ezininzi zeekliniki kwakufuneka zibonise ukuba zinokubonelela ngempumelelo intlungu e- fibromyalgia , ukukhathala kunye nomgangatho wobomi.
Nangona kunjalo, iLyrica ayisebenzi kuwo wonke umntu nge-fibromyalgia.
Enyanisweni, ukuhlaziywa okushicilelwe ngo-2016 kwafumanisa ukuba iLyrica yayiphumelele ngokufanelekileyo kwi-39 ekhulwini yabathathi-nxaxheba abaye bathatha i-300 mg ngosuku, kunye nama-43 ekhulwini abo bathatha 600 mg ngosuku. Lezo zibalo zibonakala zithembise ngokuqinisekileyo de ucinga ukuba iipesenti ezingama-28 zabantu abathatha indawo ye-placebo benza kanye.
Olunye uphando lubonisa ukuba izidakamizwa ezintathu ze-FDA-ezivunyiweyo ze-fibromyalgia-iLyrica, iCymbalta, ne-Savella-zizonke malunga nokusebenza ngokulinganayo. Ukudibanisa ezimbini izidakamizwa kunokuba luncedo, nangona kunjalo. Ucwaningo lwango-2016 olupapashwe kwiphephancwadi I- Pain ibonisa ukuba ukudibanisa iLyrica kunye neCymbalta kunokusebenza ngokugqithiseleyo kunokuba kukho izidakamizwa ngokwazo, kwaye abalobi banxuse uphando oluninzi kwiinkqubo zonyango.
Isistim
I-dose evamile yeLyrica kwi-fibromyalgia i-300 mg ukuya kuma-600 mg ngosuku, ukwahlukana phakathi kwamanani amabini okanye amathathu. Ngokuqhelekileyo, oogqirha batusa ukuba baqale kumlinganiselo ophantsi, njengama-75 mg kabini ngosuku, kwaye basebenze ngokukhawuleza kwiqondo elithile.
Ukuba unquma ukuphuma eLyrica, xela ugqirha wakho malunga nendlela efanelekileyo yokucima. Kuyingozi ukuyeka ukuthatha uLyrica ngokukhawuleza.
Imiphumela
Ngo-2016 ukuhlaziywa kweprojekthi yezokhuseleko yaseLyrica, abaphandi bafumanisa ukuba iimiphumo ezingekho phantsi kwezinto ezimbi zihlala zilula kwaye ziphakathi kwaye abantu abaninzi banakho ukuzinyamezela ixesha elide.
Olunye uphando lubonisa ukuba kuphela iipesenti ezili-10 abantu abaye baphuma ngenxa yemiphumo emibi evela eLyrica kunokuba bevela kwindawo ye-placebo.
Nangona kunjalo, uluhlu lweempembelelo ezingasetyenziswayo lude. Ezinye zizinzulu ngokwaneleyo ukuba uqhagamshelane nodokotela wakho ngokukhawuleza ukuba unayo. Ziquka:
- Ukuphendulela okuvakalayo (ukukhawuleza, ukubetha, ukuvuthwa, ubuso obuvuvukileyo, imilomo okanye ulwimi)
- Ukukhathazeka / ukudideka
- Iingxaki zokuphefumula
- Umbono utshintsha
- Iintlungu zesifuba
- Ukunyakaza okungaqhelekanga kokunyanzelisa
- Ukulahleka kwememori
- Ubuhlungu besisu, ububele okanye ubuthathaka
- Ukugubha
- Ukuqhwala okanye ukuphuma
- Imiba yokuzibulala okanye yokufa
- Umoya utshintsha
Imiphumo echaphazelekayo yaseLyrica eqhelekileyo, ngokuqhelekileyo ayifuni ukunakekelwa ngonyango, iquka:
- Ukutyunjwa okanye urhudo
- Umlomo omile
- Intloko
- Ukungabikho
- I sizathu
- Ukutyeba kwakho
Uphando lufumene ukuba iLyrica ayikho nto ibangela ukusebenzisana kakubi kunye nezinye iziyobisi kwaye kubonakala ngathi zikhuselekile xa zidibaniswe nezidandlululo.
ILizwi
Wena kunye noogqirha bakho kuphela abanokugqiba ukuba kufuneka unike uLyrica uzame. Yazi ukuba inokuba yindleko kwaye iinkampani zomshuwalense aziyi kuhlawula.
Kwakhona ingcinga efanelekileyo, xa uqala iyeza elitsha, ukuba ikhemistiki yakho ibheke uluhlu lwakho lweziyobisi naluphi na ukusebenzisana okungalunganga. Ungaphinda ufune ukuqwalasela uluhlu lwezityalo ezichaphazelekayo ukuze ukwazi ukukhawuleza ukuba unobungozi.
Imithombo:
Derry S, Cording M, Wiffen PJ, et al. Pregabalin ngenxa yentlungu e-fibromyalgia kubantu abadala. Isiseko seenkcukacha zeCochrane zokuphononongwa ngokuchanekileyo. 2016 Sep 29; 9: CD011790. [Epub ngaphambi kokuprinta]
Gerardi MC, Atzeni F, Batticciotto A, et al. Ukhuseleko lwe-pregabalin kunyango lwe-fibromyalgia. Iingcamango zengcali malunga nokukhuselwa kweziyobisi. 2016 Oktobha 11: 1-8. [Epub ngaphambi kokuprinta]
> Gilron I, Chaparro LE, Tu D. Pain. Umxube we-pregabalin kunye ne-duloxetine ye-fibromyalgia: ityala elilawulwa ngokungahleliwe. 2016 Jul; 157 (7): 1532-40.
> Lee YH, ingoma yeGG. Ukuqhathaniswa nokuqhathaniswa kwe-duloxetine, pregabalin, kunye ne-milnacipran ukwenzela unyango lwe-fibromyalgia: inethiwekhi ye-besiesi ye-betaesi ye-meta-analysis of trials. Rheumatology ngamazwe ngamazwe. Ngo-2016 ngoMeyi; 36 (5): 663-72.
Upapasho lweNIH NO. 04-5326